Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 15/20 | 0.53 |
| ▸ | CTSG | P08311 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9539391 | 0.94 | ELANE (0.53) | ELANECTSGKDM4EHTR1B | |
| Hydrochloric Acid SCHEMBL9542178 | 0.89 | ELANE (0.51) | ELANECTSGKDM4EKCNA3 | |
| Hydrochloric Acid SCHEMBL9538665 | 0.89 | ELANE (0.51) | ELANECTSGKDM4EKCNA3 | |
| Hydrochloric Acid SCHEMBL9539416 | 0.83 | ELANE (0.51) | ELANECTSGKDM4EKCNA3 | |
| Hydrochloric Acid SCHEMBL9540764 | 0.83 | ELANE (0.51) | ELANECTSGKDM4EKCNA3 | |
| SCHEMBL9542191 | 0.83 | MAOA (0.53) | ELANECTSGKDM4EKCNA3HTR1B | |
| SCHEMBL16226244 | 0.80 | ELANE (0.76) | ELANECTSG | |
| SCHEMBL11604034 | 0.80 | KCNA3 (0.65) | KDM4EKCNA3HTR1B | |
| SCHEMBL9539438 | 0.80 | ELANE (0.48) | ELANECTSGKDM4E | |
| Hydrochloric Acid SCHEMBL11604535 | 0.79 | KCNA3 (0.63) | KDM4EKCNA3HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1993005054-A1 | OXAZAPHOSPHORINES USEFUL AS ANTITUMOR AGENTS, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1993-03-18 | — | — | WO | disclosed |